



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Visibility of patient input throughout scientific procedures

PCWP plenary meeting


Presented by Maria Mavris on 25 September 2018
Public Engagement Department



An agency of the European Union



Patient involvement along the medicine lifecycle at EMA





Annual reports (and highlights)



Started in 2007 as progress reports
Interactions
Then HCP
Now Public Engagement Report

Visibility of patient input throughout scientific procedures





Press releases

[News and press releases](#)

[Events](#)

[What's new](#)

[Committee highlights](#)

[Therapeutic areas: latest updates](#)

[Publications](#)

[Press and social media](#)

[Open consultations](#)

[RSS feeds](#)

[Home](#) [News and Events](#) [News and press releases](#)

Involving young people in EMA activities

[News](#)

19/07/2017

Involving young people in EMA activities

New principles give a voice to patients and consumers under age 18

The European Medicines Agency (EMA) has agreed on principles for involving patients and consumers under the age of 18 in the activities of its scientific committees and working parties.

Young patients and consumers can make an important contribution to EMA's committee discussions on medicines by sharing their experience and perspectives of living with a disease or condition. These working principles set out best practice for the interaction between scientific committees or working parties and young people under 18 years old, for example, discussion in small groups, provision of specific support, use of appropriate language, etc. They also address issues such as obtaining parental consent, protection of personal data and the privacy of the young patients.

The principles define what input young people could contribute and suggest options on how best to capture their opinions. The document also establishes a process for identifying, supporting and consulting with young people.

According to the new principles, involving young people in the Agency's activities will be considered on a case-by-case basis when it is expected that their views could enhance scientific discussions related to the development and assessment of medicines for children and adolescents.

The key forum in which young people could participate in the Agency's activities would be its Paediatric Committee (PDCO), but experience has demonstrated that the Committee for Medicinal Products for Human Use (CHMP), the Pharmacovigilance Risk Assessment Committee (PRAC) and the Scientific Advice Working Party (SAWP) can also benefit from this input when these groups review medicines for children.

Since its creation, the Agency has engaged in dialogue with patients, consumers and carers. They are involved in almost all areas of the Agency's activities. However, one area where interaction had not yet been established was the option to consult with people under the age of 18.

[News and press releases](#)

[Events](#)

[What's new](#)

[Committee highlights](#)

[Therapeutic areas: latest updates](#)

[Publications](#)

[Press and social media](#)

[Open consultations](#)

[RSS feeds](#)

[Home](#) [News and Events](#) [News and press releases](#)

Involving patients in discussions on benefits and risks of medicines

[News](#)

08/05/2017

Involving patients in discussions on benefits and risks of medicines

EMA publishes report on CHMP pilot project

The European Medicines Agency (EMA) has published a final report on the experience gained during its pilot project to involve patients directly in the assessment of the benefits and risks of medicines in its Committee for Medicinal Products for Human Use (CHMP).

The report concludes that patients should continue to be invited to oral explanations when their input could be valuable to the assessment of a medicine. This could be the case, for example, when the Committee is considering whether to recommend the authorisation of a new medicine or the maintenance, suspension or revocation of an existing authorisation, or a restriction of indication of an authorised medicine.

During the pilot, which ran from September 2014 to December 2016, patients participated in discussions at the CHMP and gave their views on the benefits and risks of the following medicines:

- **Scenesse** (afamelanotide) for the treatment of erythropoietic protoporphyria (EPP) (September 2014);
- **Intuniv** (guanfacine) for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents (June 2015);
- **Tecfidera** (dimethyl fumarate) for the treatment of multiple sclerosis (October 2015);
- **Kyndria** (dantrolene) for the treatment of Duchenne muscular dystrophy (May 2016);
- **Translarna** (ataluren) for the treatment of Duchenne muscular dystrophy (June 2016);
- **Translarna** (ataluren) for the treatment of Duchenne muscular dystrophy (November 2016).

After each case, feedback was obtained from the patients and the CHMP members who were involved in order to analyse the participation and contribution of the patients. The feedback from CHMP members and patients was positive and confirmed the benefit of involving patients in discussions at the CHMP when the patient perspective could complement the assessment.

The CHMP will continue to involve patients in CHMP oral explanations when it is felt this could be of benefit.

Communication
to the general
public and the
media

Webpage and landing pages



Site-wide search [GO](#)

[Advanced document search](#)

[Home](#) [Find medicine](#) [Human regulatory](#) [Veterinary regulatory](#) [Committees](#) [News & events](#) [Partners & networks](#) [About us](#)

Search for medicines

Search our database of medicines - including human medicines, veterinary medicines and herbal medicines.

[Quick search](#)

Or go to the medicines section for more options to help you find what you need.

Improving understanding of biosimilars

EMA and the European Commission have published new information material on biosimilars in several European Union languages.

[Read more...](#)

Find information for...

[Patients and carers](#)

[Healthcare professionals](#)

[Animal health professionals](#)

[Pharmaceutical industry](#)

[Media](#)

[Academia](#)

[Product emergency](#)

[Latest news](#) [Patient safety](#) [New medicines](#) [Public consultations](#)

14/09/2018 **Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 11-13 September 2018**

CVMP invites comments on a reflection paper dealing with resistance development of certain antimicrobials and its impact on human and animal health ... [Read more](#)

13/09/2018 **Committee for Orphan Medicinal Products (COMP) elects new chair**

Violeta Stoyanova-Beninska to begin three-year mandate at October meeting ... [Read more](#)

13/09/2018 **Improving understanding of biosimilars in the EU**

Find information for...

[Patients and carers](#)

[Healthcare professionals](#)

[Animal health professionals](#)

[Pharmaceutical industry](#)

[Media](#)

[Academia](#)

Featured information



Improving understanding of biosimilars

EMA and the European Commission have published information materials on biosimilar medicines to improve understanding of these medicines in the

European Union. This includes an animated video and information guides for patients and healthcare professionals in several European languages.



Communication at EMA

EMA has published the results of its 2017 stakeholder survey on its communication activities to the public. These will inform ongoing and future activities.



Stakeholder engagement report 2017

EMA has published its 2017 annual report on its interactions with patients, consumers, healthcare professionals, academics and their organisations, incorporating both quantitative and qualitative data.



Joint meeting of patients and consumers and healthcare professionals working parties

During their April meeting, the Patients' and Consumers' Working Party (PCWP) and the Healthcare Professionals' Working Party (HCPWP) discussed recent learnings and trends around health, social media, real-world evidence, electronic product information and the findings of the survey on additional monitoring awareness. EMA provided an update on its relocation to Amsterdam, clinical data publication policy and implementation of the Clinical Trial Regulation.

Working Party (HCPWP) discussed recent learnings and trends around health, social media, real-world evidence, electronic product information and the findings of the survey on additional monitoring awareness. EMA provided an update on its relocation to Amsterdam, clinical data publication policy and implementation of the Clinical Trial Regulation.



Paediatric Regulation workshop report

EMA has published its workshop report on how to better apply the Paediatric Regulation to boost development of medicines for children. It also produced a

factsheet and a video¹⁰ for insights and views of this regulation. For more information, see Paediatric medicines: Overview.

Social media



Visibility of patient input throughout scientific procedures

Training



Attendance at meetings and conferences



Targeted emailing



Organisations

Individuals

Stakeholder database

Visibility of patient input throughout scientific procedures

Getting involved

Email Print Help Share

Patients, consumers and carers are involved in a wide range of European Medicines Agency (EMA) activities.

They are involved as either representatives of European Union (EU) patients' and consumers' organisations, representatives of their own organisation or as individual experts depending on the nature of the activity.

Individual expert database

Register as Patient expert

Patients representing patients' organisations	Patients representing their organisation	Patients as individual experts
- Management Board - Scientific Committee(s)	- Patients' and Consumers' Working Party (PCWP) - EMA consultations - Workshops	- Scientific advice / protocol assistance procedures - Scientific advisory / ad hoc expert groups - Scientific committee consultations - Review of documents

Related content

- Patients and consumers
- Eligible patients' and consumers' organisations
- Patients' and Consumers' Working Party
- Training and support for patients and consumers
- Key documents

- **432 individuals registered**
- **304 organisations registered**



Topic Group on visibility created

Acknowledge and promote visibility of patient input into the Agency's activities



Annex 1

Recommendations from the PCWP topic group on acknowledging and promoting visibility of patients' input in the Agency's activities Adopted on 26 November 2015

As part of its activities, the PCWP identified the need to raise awareness of the involvement of patients, consumers and their organisations in the work of the EMA and also to further acknowledge the value of their input.

The topic group was created to:

- Explore how to raise awareness and visibility of patients/consumers work at the EMA;
- Explore how to best acknowledge patients/consumer input in the context of the activities of scientific committees, working parties, scientific advisory groups and other expert groups;
- Make recommendations.

In order to get a better understanding of the current status and generate new ideas, the 2 co-leaders prepared a survey which was distributed to the 13 topic group members.

9 organisations answered. The questionnaire is attached in annex.

On the basis of the outcome of the questionnaire, the topic group agreed on the following recommendations:

Organisations acknowledge and promote recognition: Pre-requisites

- EMA to provide clear guidance on "confidentiality versus transparency" boundaries (organisations refrain to communicate on patients' involvement to avoid breach of confidentiality);
- EMA and organisations acknowledge that patients may refuse to be named (risk of stigma) and protection of private data has to be respected.

How to improve acknowledgement and promotion of patient input into EMA activities by EMA

- EMA to provide a certificate of attendance to meetings;

20 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

Telephone: +44 (0)20 5066 6000 • Telex: 310 631 1234 • Fax: +44 (0)20 5066 6000

Send a question via our website www.ema.europa.eu/en/contact

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.



Annual Report: Follow up survey/working group?

Annual Report

- Review each section of the annual report
- Which information do you use?
- Which information is nice to know?
- Infographics of highlights



Any questions?

Further information

[Insert relevant information sources or contact details as applicable.]

European Medicines Agency

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555

Send a question via our website www.ema.europa.eu/contact

Follow us on  **@EMA_News**